

## Pharmaceutical Pipeline Submission Guidelines Deadline: 15 February 2019

Pharmaceutical Pipeline Submitters – Your application will be submitted under the "Pharmaceutical Pipeline" submission type. Pharmaceutical Pipeline submissions should include those with early clinical data (Phase 1 and 2) on compounds for which Phase 3 data had not been presented. The goal is to generate enthusiasm for the many novel compounds under exploration, most of which have not reached Phase 3. This is not to exclude presentations of clinical data on compounds currently in Phase 3 targeted to truly untested mechanisms, since such data would also be of great interest.

- Pharmaceutical Pipeline submissions should be structured as: Background, Methods, Results and Discussion.
- There is a limit of 3200 characters, not counting spaces, for the text of your abstract submission. No images, graphs, or tables will be accepted.
- Submissions by women and minorities are highly encouraged.
- Note: Pharmaceutical Pipeline abstracts will not be included in the online abstract publication.